Table 3.
N | Lesions requiring drainage per outcome |
Sensitivity, % (95% CI) |
Specificity, % (95% CI) |
PPV (95 % CI) |
NPV (95% CI) |
|
---|---|---|---|---|---|---|
Clinically evident (n=228) | ||||||
Study/treating MD CE+ | 156 | 144 | 94.7 (90.2 to 97.9) |
84.2 (74.7 to 91.7) |
92.3 (87.3 to 96.3) |
88.9 (80.2 to 95.3) |
Study/treating MD CE− | 72 | 8 | ||||
Study MD CE+EUS + | 147 | 134 | 93.1 (88.4 to 96.6) |
81.4 (70.9 to 90.0) |
91.2 (85.8 to 95.4) |
85.1 (76.1 to 92.5) |
Study MD CE+EUS − | 67 | 10 | ||||
Study MD CE+EUS uncertain | 14 | 8 | ||||
Difference |
−1.7 (−3.4 to 0) |
−2.8 (−9.7 to 3.2) |
−1.2 (−3.8 to 1.7) |
−3.8 (−7.2 to 0.2) |
||
Not clinically evident (n=159) | ||||||
Study MD CE+ | 40 | 19 | 43.7 (0.0 to 85.3) |
42.0 (0.0 to 79.5) |
42.9 (0.0 to 66.7) |
45.6 (0.0 to 71.4) |
Study MD CE− | 34 | 16 | ||||
Study MD CE uncertain | 85 | 52 | ||||
Study MD CE+EUS + | 83 | 59 | 77.6 (58.2 to 89.7) |
61.3 (45.6 to 71.2) |
71.1 (62.5 to 79.5) |
69.1 (56.5 to 79.1) |
Study MD CE+EUS − | 55 | 17 | ||||
Study MD CE+EUS uncertain | 21 | 11 | ||||
Difference |
33.9 (1.2 to 66.6) |
19.3 (−13.8 to 52.4) |
28.2 (8.8 to 47.6) |
23.2 (0.6 to 45.8) |